A Cell-Free DNA Plasma Next-Generation Sequencing Test—Is It Worth the Cost?
Pathogens · 15.08.2025 · 14 (8) · 811
DOI: 10.3390/pathogens14080811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 15.08.2025. Verfasst von Sean Jung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
The Karius Test (KT), a microbial cell-free DNA next-generation sequencing assay, is increasingly utilized in challenging infectious syndromes. However, its real-world clinical utility and cost-effectiveness remain uncertain.
Methods
We conducted a retrospective review of 88 KT results from adult patients at UC San Diego Health between July 2017 and April 2024. Each case was evaluated for clinical impact using standardized criteria. We analyzed diagnostic yield, turnaround time, number needed to test (NNT), and institutional billing data for reimbursement and cost implications.
Results
Of 88 unique tests, forty-nine (55.7%) identified at least one pathogen. Eleven (12.5%) had a positive clinical impact—eight provided the only microbiologic diagnosis, and three were faster than conventional methods. Vascular/graft infections showed the highest yield. Twenty-one tests had a neutral impact; fifty-six showed no clinical benefit. The Median turnaround time was 3 days. The NNT was 6.1 or 2.75 including neutral cases. Cost analysis revealed a substantial financial burden without transparent reimbursement mechanisms in inpatient settings.
Conclusion
The KT demonstrates modest clinical utility with noteworthy benefits in select scenarios. Given its high cost and variable impact, we advocate for diagnostic stewardship led by infectious disease specialists to optimize test use and minimize unnecessary expense.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA.
- Infection Prevention and Clinical Epidemiology and Antimicrobial Stewardship Programs, University of California San Diego Health, San Diego, CA 92103, USA.
- Department of Pathology, Center for Advanced Laboratory Medicine, University of California San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Francesca Torriani, Shira Abeles
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Jung, S., Torriani, F., Abeles, S., & Kline, A. (2025). A Cell-Free DNA Plasma Next-Generation Sequencing Test—Is It Worth the Cost?. Pathogens, 14(8), 811. https://doi.org/10.3390/pathogens14080811
Vancouver
Jung S, Torriani F, Abeles S, Kline A. A Cell-Free DNA Plasma Next-Generation Sequencing Test—Is It Worth the Cost?. Pathogens. 2025;14(8):811. doi:10.3390/pathogens14080811
BibTeX
@article{Jung2025,
author = {Jung, Sean and Torriani, Francesca and Abeles, Shira and Kline, Ahnika},
title = {A Cell-Free DNA Plasma Next-Generation Sequencing Test—Is It Worth the Cost?},
journal = {Pathogens},
year = {2025},
volume = {14},
number = {8},
pages = {811},
doi = {10.3390/pathogens14080811}
}
EUVIMED